PubRank

Mark E Dudley

Author PubWeight™ 187.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 16.96
2 Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008 9.82
3 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 9.24
4 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011 9.19
5 Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010 9.13
6 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011 9.03
7 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
8 Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012 7.39
9 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010 7.25
10 Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014 6.88
11 Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009 6.17
12 Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009 5.33
13 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013 4.80
14 Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004 4.73
15 PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014 3.54
16 Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005 3.49
17 Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013 3.45
18 High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003 3.39
19 T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010 3.29
20 Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006 3.15
21 Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2004 3.05
22 Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004 2.70
23 Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008 2.57
24 Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012 2.25
25 T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 2004 2.11
26 Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2004 1.99
27 Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005 1.91
28 TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012 1.78
29 Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009 1.78
30 Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011 1.62
31 The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012 1.61
32 Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 2003 1.55
33 Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010 1.52
34 Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol 2013 1.50
35 Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006 1.44
36 Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012 1.43
37 Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008 1.38
38 Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010 1.35
39 Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010 1.31
40 Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol 2004 1.25
41 Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 2012 1.24
42 New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012 1.23
43 Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother 2010 1.21
44 Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther 2008 1.17
45 Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 2012 1.09
46 Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 2002 1.07
47 Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 2009 1.05
48 A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 2010 1.03
49 Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J Transl Med 2012 0.98
50 Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 2013 0.97
51 A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A 2007 0.96
52 Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 2012 0.94
53 Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg 2012 0.94
54 Cancer immunotherapy. N Engl J Med 2008 0.94
55 Bioreactors get personal. Oncoimmunology 2012 0.90
56 Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J Immunother 2009 0.88
57 IRF5 gene polymorphisms in melanoma. J Transl Med 2012 0.86
58 Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 2012 0.85
59 Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol 2009 0.85
60 Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother 2011 0.81
61 Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. J Thorac Cardiovasc Surg 2010 0.79
62 Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol 2012 0.79
63 Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunol Immunother 2004 0.78
64 A stimulating presentation. Nat Biotechnol 2002 0.75
65 A major player "gets in the act". J Immunother 2012 0.75